<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03329508</url>
  </required_header>
  <id_info>
    <org_study_id>P2B001/003</org_study_id>
    <nct_id>NCT03329508</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study With P2B001 in Subjects With Early Parkinson's</brief_title>
  <official_title>A Phase 3, Twelve-week Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to Its Individual Components in Subjects With Early Parkinson's Disease and to a Calibration Arm of Pramipexole ER.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharma Two B Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharma Two B Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy,
      Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily
      Compared to its Individual Components in Subjects With Early Parkinson's Disease and to a
      Calibration Arm of Pramipexole ER.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 525 eligible subjects with early untreated Parkinson's disease (PD), will be
      randomized to 4 treatment groups. Each subject will participate in the study for
      approximately 18 weeks including a 30 day screening period, 12 week treatment period, and 2
      weeks follow-up period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>4 arms</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>double blind study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>change in total Unified Parkinson's Disease Rating Scale (UPDRS) score (defined as sum of parts II and III, scores (0-160).</measure>
    <time_frame>baseline to week 12</time_frame>
    <description>Superiority of P2B 0.6/0.75 mg as compared to its individual components in the change of total UPDRS score (defined as sum of parts II and III, scores (0-160).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Epworth Sleepiness Scale (ESS) score.</measure>
    <time_frame>baseline to week 12</time_frame>
    <description>Superiority of P2B 0.6/0.75 mg as compared to pramipexole ER in the change of Epworth Sleepiness Scale (ESS) score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of Total Parkinson's Disease Questionnaire 39 (PDQ39) score.</measure>
    <time_frame>baseline to week 12</time_frame>
    <description>The efficacy of P2B 0.6/0.75 mg as compared to its individual components in the change of Total PDQ39 score.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">525</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>P2B001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose combination once daily capsule of pramipexole and rasagiline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rasagiline capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rasagiline Once daily capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pramipexole capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pramipexole once daily capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pramipexole Extended Release</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pramipexole ER tablet titrated to optimal dose of 1.5, 3.0 or 4.5mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>P2B001</intervention_name>
    <description>Fixed dose once daily combination capsule of pramipexole and rasagiline</description>
    <arm_group_label>P2B001</arm_group_label>
    <other_name>Fixed dose combination of Pramipexole and rasagiline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rasagiline</intervention_name>
    <description>Rasagiline oral capsule</description>
    <arm_group_label>rasagiline capsule</arm_group_label>
    <other_name>rasagiline capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pramipexole</intervention_name>
    <description>Pramipexole low dose oral capsule</description>
    <arm_group_label>Pramipexole capsule</arm_group_label>
    <other_name>Pramipexole capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pramipexole ER</intervention_name>
    <description>Pramipexole ER titrated to optimal dose</description>
    <arm_group_label>Pramipexole Extended Release</arm_group_label>
    <other_name>Pramipexole Extended Release Oral Tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has Parkinson's disease consistent with the UK Brain Bank Criteria and must
             have bradykinesia with sequence effect. If rest tremor does not exist must have
             prominent asymmetry of motor function.

          2. Subject with disease duration less than 3 years.

          3. Subject has a H&amp;Y stage score of &lt; 3.

          4. Subject has a MMSE score â‰¥ 26.

        Exclusion Criteria:

          1. Subject has an atypical parkinsonian syndrome or secondary parkinsonism

          2. Subject has previous exposure to levodopa or a dopamine agonist for longer than 4
             weeks; if previous exposure was less than 4 weeks then it must not be within 2 months
             prior to the baseline visit.

          3. Subject has previous exposure to a MAO-B inhibitor for longer than 4 weeks; if
             previous exposure was less than 4 weeks then it must not be within 3 months prior to
             the baseline visit.

          4. Subject who has taken anticholinergic drugs for PD or amantadine for longer than 4
             weeks; if previous exposure was less than 4 weeks then it must not be within 1 month
             prior to the baseline visit.

          5. Subject has moderate (Child-Pugh categorization B, score 7-9) or severe (Child-Pugh
             categorization C, score 10-15) hepatic impairment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pninit Litman</last_name>
    <role>Study Director</role>
    <affiliation>Pharma2b LTD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Avigail Glass</last_name>
    <phone>89472672</phone>
    <email>Avigail@pharma2b.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pninit Litman</last_name>
    <email>pninit@pharma2b.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>P2B001/003 Site Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Ortega Palacios</last_name>
      <email>susan@movementdisorders.us</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P2B001 site Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Barles</last_name>
      <email>gina.barles@med.usc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Site Sacramento</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Siobhan Vasquez</last_name>
      <email>skvasquez@ucdavis.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P2B001 Study Vernon</name>
      <address>
        <city>Vernon</city>
        <state>Connecticut</state>
        <zip>06066</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheila Thurlow</last_name>
      <email>thurlow@uchc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P2B001/003 site Boca Raton</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33431</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Letty Ginsburg</last_name>
      <email>lginsburg@med.miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Site Boca Raton</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisbeth Carvajal</last_name>
      <email>lcarvajal@ParkinsonsCenter.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P2B001/003 site Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Padron</last_name>
      <email>npadron@med.miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Site Port Charlotte</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33980</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zachary Lee</last_name>
      <email>research@parkinsonsfl.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Site Sarasota</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jillian Chaykin</last_name>
      <email>jchaykin@roskampinstitute.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Site Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leigh Harrell</last_name>
      <email>leighharrell@health.usf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Site Augusta</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Buff Farrow</last_name>
      <email>bfarrow@augusta.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P2B001/003 site Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Kelly</last_name>
      <email>Brian_J_Kelly@rush.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Site Winfield</name>
      <address>
        <city>Winfield</city>
        <state>Illinois</state>
        <zip>60190</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Hansen</last_name>
      <email>kathy.hansen@nm.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P2B001/003 site Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>April Langhammer</last_name>
      <email>alanghammer@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Site Lexington</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Wagner</last_name>
      <email>renee.wagner@uky.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P2B001/003 site Baton Rouge</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Alumbaugh</last_name>
      <email>gcalegan@interspond.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Site East Lansing</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doozie Russell</last_name>
      <email>doozie.russell@ht.msu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Site Golden Valley</name>
      <address>
        <city>Golden Valley</city>
        <state>Minnesota</state>
        <zip>55427</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pat Ede</last_name>
      <email>patricia.ede@parknicollet.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P2B001/003 site St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Ammel</last_name>
      <email>ammelm@neuro.wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Site Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Gardella</last_name>
      <email>researchli@parkinsonscenter.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Site Asheville</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Woodard</last_name>
      <email>research@ashneuro.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Site Toledo</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Spears</last_name>
    </contact>
    <contact_backup>
      <email>julia.spears@utoledo.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>P2B001/003 site Bedford</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Snowden</last_name>
      <email>heathersnowden@ntmdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P2B001/003 Site Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mina Zilaie</last_name>
      <email>Mina.Zilaie@UTSouthwestern.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>October 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
    <mesh_term>Rasagiline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

